Omeros confident of strong reception for eye product by eye surgeons
This article was originally published in Scrip
Executive Summary
Presenting analyses of Phase II and III data on OMS302, Omeros Corporation said it expects the ophthalmology product will be 'widely and rapidly adopted by ophthalmologic surgeons' carrying out lens replacement surgeries.